Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (1-10 of 172) with videos related to

Pageof 18
Sort By:
Cleveland Clinic Journal of Medicine|February 23, 2008
Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seenJonathan Kay
Nature Clinical Practice. Rheumatology|August 30, 2008
Nephrogenic systemic fibrosis: a new concern for rheumatologistsJonathan Kay
Nature Reviews. Rheumatology|December 25, 2019
Overcoming barriers to biosimilars in inflammatory arthritisJonathan Kay
The Lancet. Rheumatology|January 22, 2024
Multiple switching studies and interchangeability of biosimilarsJonathan Kay
Rheumatic Diseases Clinics of North America|July 7, 2019
Are There Benefits and Risks to Biosimilars from a Patient Perspective?Jonathan Kay
Journal of Internal Medicine|April 17, 2019
A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extensionJonathan Kay
Rheumatic Diseases Clinics of North America|April 20, 2013
Rheumatic rarities. PrefaceJonathan Kay
Journal of Cardiothoracic and Vascular Anesthesia|August 23, 2024
Where Did the Mass Go? Complex "Aortic Valve Lesion" Disappears Between Preoperative Echocardiography and the Operating RoomJonathan Kay
Clinical Chemistry and Laboratory Medicine|May 30, 2006
Technology to improve quality and accountabilityJonathan Kay
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
Editorial: Biosimilars: New or Déjà Vu?Jonathan Kay
Pageof 18

Showing results (1-10 of 172) with videos related to

Sort By:
Pageof 18
Cleveland Clinic Journal of Medicine|February 23, 2008
Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seenJonathan Kay
Nature Clinical Practice. Rheumatology|August 30, 2008
Nephrogenic systemic fibrosis: a new concern for rheumatologistsJonathan Kay
Nature Reviews. Rheumatology|December 25, 2019
Overcoming barriers to biosimilars in inflammatory arthritisJonathan Kay
The Lancet. Rheumatology|January 22, 2024
Multiple switching studies and interchangeability of biosimilarsJonathan Kay
Rheumatic Diseases Clinics of North America|July 7, 2019
Are There Benefits and Risks to Biosimilars from a Patient Perspective?Jonathan Kay
Journal of Internal Medicine|April 17, 2019
A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extensionJonathan Kay
Rheumatic Diseases Clinics of North America|April 20, 2013
Rheumatic rarities. PrefaceJonathan Kay
Journal of Cardiothoracic and Vascular Anesthesia|August 23, 2024
Where Did the Mass Go? Complex "Aortic Valve Lesion" Disappears Between Preoperative Echocardiography and the Operating RoomJonathan Kay
Clinical Chemistry and Laboratory Medicine|May 30, 2006
Technology to improve quality and accountabilityJonathan Kay
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
Editorial: Biosimilars: New or Déjà Vu?Jonathan Kay
Pageof 18